Form 4: Pacira CCO Granted 51,714 Restricted Stock Units

Pacira BioSciences' Chief Commercial Officer, Brendan Teehan, was granted 51,714 restricted stock units, vesting over four years.

Summary

• Brendan Teehan, Chief Commercial Officer of Pacira BioSciences, Inc. (PCRX), was granted 51,714 restricted stock units (RSUs).
• The transaction date for this grant was February 11, 2026.
• These RSUs vest in four equal annual installments, commencing on February 15, 2027.
• Vesting is contingent upon Mr. Teehan's continuous service with Pacira BioSciences.
• Each restricted stock unit represents the contingent right to receive one share of the issuer's common stock.
• Following this transaction, Mr. Teehan beneficially owns 100,934.268 shares of common stock.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive signal, indicating executive retention and alignment of interests, which is generally favorable for corporate governance and long-term stability.

Positives

• The grant of restricted stock units aligns management's interests with long-term shareholder value.
• The multi-year vesting schedule encourages the retention of a key executive within the company.

Negatives

• There is no immediate cash inflow for the executive, as these are restricted stock units with a future vesting schedule.

Risks

• The vesting of the restricted stock units is contingent on the reporting person's continuous service with the issuer as of each vesting date.

Future Outlook

The restricted stock units are scheduled to vest in four equal annual installments, beginning on February 15, 2027, provided the reporting person maintains continuous service with the issuer.

Industry Context

StockSavvy.ai notes that RSU grants are a common form of executive compensation in the biotechnology and pharmaceutical industries, designed to incentivize long-term performance and retention of key talent.

Comparison to Industry Standards

• Restricted stock unit grants with multi-year vesting schedules are standard practice across many industries, including biotech, for executive compensation.
• Companies like Amgen (AMGN) and Gilead Sciences (GILD) frequently utilize similar equity compensation structures to align executive incentives with shareholder interests and ensure retention of key talent.

Related Party Transactions

• The grant of 51,714 restricted stock units to Brendan Teehan, the Chief Commercial Officer, constitutes a related party transaction as it involves compensation from the issuer to an executive officer.

Stakeholder Impact

• Shareholders: Potential positive impact due to increased alignment of executive interests with long-term company performance and retention of a key officer.
• Employees: May signal stability in executive leadership and a commitment to retaining key personnel.

Next Steps

• The restricted stock units will vest in four equal annual installments beginning on February 15, 2027.

Key Dates

Recommendation

This Form 4 reports a routine executive compensation grant of restricted stock units, which is a standard practice for retaining key personnel and aligning their interests with long-term shareholder value. It does not provide new information that would significantly alter the company's fundamental outlook or warrant a change in investment recommendation.

Keywords

Pacira BioSciences, PCRX, Brendan Teehan, Restricted Stock Units, RSU grant, insider transaction, executive compensation, Form 4